Decheng Capital China Life Sciences USD Fund III, L.P.'s Form 4 filing
Alpine Immune Sciences, Inc. (ALPN) · filed Sep 21, 2021
- Accession no.
- 0001626199-21-000118
- Filed
- Sep 21, 2021, 6:39 PM ET
- Trade date
- Sep 17, 2021
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $14.5M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Decheng Capital China Life Sciences USD Fund III, L.P.CIK 0001736814 | 10% Owner |
| Decheng Capital Management III (Cayman), LLCCIK 0001747821 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 17, 2021 | Common Stock | PPurchaseAcquired | +1,542,553 | $9.40 | +$14,499,998.2 | 4,708,288 | Direct | Duplicate filing |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.